CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Biopharma to Host Conference Call to Provide Second Quarter 2019 Business Update

5 Jul 2019, 12:00
On 18 July 2019, at 08:00 CET, Hansa Biopharma will publish its Business Update for the second quarter of 2019. 

All interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 13:00 CET. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under Events & Webcast, and will also be made available online after the call. To participate in the telephone conference, please use the dial in details shown below:

SE: +46 850-558 352
UK: +44 3333 009 267
US: +1 833 823 0590

A link to audio cast can be found on the Hansa Biopharma website under Events & Webcasts or here:

https://financialhearings.com/event/11685

The information was submitted for publication, through the agency of the contact person set out below at 12:00 CET on July 5, 2019

Files

For further information, please contact:

Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com

Rolf Gulliksen, Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 733-328 634
E-mail: rolf.gulliksen@hansabiopharma.com

About Hansa Biopharma

Hansa Biopharma AB (NASDAQ Stockholm: HNSA) is harnessing its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product, IDEFIRIX (imlifidase), is a unique antibody-degrading enzyme in late-stage clinical development to enable kidney transplantation in highly sensitized patients, with additional clinical studies in acute autoimmune indications. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden.